Portal de Periódicos da CAPES

Clinical experience with next-generation sequencing–based liquid biopsy testing for cancer detection in dogs: a review of 1,500 consecutive clinical cases

2023; American Veterinary Medical Association; Volume: 261; Issue: 6 Linguagem: Inglês

10.2460/javma.22.11.0526

1943-569X

Allison L. O’Kell, Katherine M. Lytle, Todd A. Cohen, Lilian K. Wong, Emily Sandford, Jill M. Rafalko, Gina Brandstetter, Lauren R. DiMarzio, Ashley Phelps‐Dunn, Michelle C. Rosentel, Chelsea D. Warren, Angela L. McCleary‐Wheeler, Patrick Fiaux, Francesco Marass, Maggie A. Marshall, Carlos A. Ruiz-Pérez, Kristina M. Kruglyak, John A. Tynan, Susan C. Hicks, Daniel S. Grosu, Jason Chibuk, Ilya Chorny, Dana W.Y. Tsui, Andi Flory,

Infectious Diseases and Mycology

Abstract OBJECTIVE To review ordering patterns, positivity rates, and outcome data for a subset of consecutive samples submitted for a commercially available, blood-based multicancer early-detection liquid biopsy test for dogs using next-generation sequencing at 1 laboratory. SAMPLE 1,500 consecutively submitted blood samples from client-owned dogs with and without clinical suspicion and/or history of cancer for prospective liquid biopsy testing between December 28, 2021, and June 28, 2022. PROCEDURES We performed a retrospective observational study, reviewing data from 1,500 consecutive clinical samples submitted for liquid biopsy testing. Outcome data were obtained via medical record review, direct communication with the referring clinic, and/or a patient outcome survey through October 16, 2022. RESULTS Sixty-four percent (910/1,419) of reportable samples were submitted for cancer screening, 26% (366/1,419) for aid in diagnosis, and 10% (143/1,419) for other indications. The positivity rate was 25.4% (93/366) in aid-in-diagnosis patients and 4.5% (41/910) in screening patients. Outcome data were available for 33% (465/1,401) of patients, and outcomes were classifiable for 428 patients. The relative observed sensitivity was 61.5% (67/109) and specificity was 97.5% (311/319). The positive predictive value was 75.0% (21/28) for screening patients and 97.7% (43/44) for aid-in-diagnosis patients, and the time to diagnostic resolution following a positive result was < 2 weeks in most cases. CLINICAL RELEVANCE Liquid biopsy using next-generation sequencing represents a novel tool for noninvasive detection of cancer in dogs. Real-world clinical performance meets or exceeds expectations established in the test’s clinical validation study.